Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line
metastatic settings, led to a raise of patients presenting with metastatic breast cancer
after treatment with these agents. Options for the treatment of patients who have progressed
after an anthracycline and a taxane are limited. The high level of in-vitro synergy of
vinflunine combined with 5-fluorouracil (5-FU) together with the good tolerance and the
encouraging response rate observed while combining IV vinflunine to oral capecitabine make it
a promising combination to investigate further in a phase III trial. This phase III trial
will evaluate the effectiveness and the safety profile of such combination for the treatment
of patient with advanced breast cancer previously treated with or resistant to anthracycline
and taxane resistant.